Oct. 29 at 9:23 PM
$LPCN All, the question/statement comes all the time about LPCN being undervalued. It is not. Biotech currently trades, on average, at about 5x annual revenues for profitable companies. LPCN, NOT PROFITABLE, trades at about 4x. They are fairly or overvalued with the facts as they are at this instant in time. Forget about pricing in the pipeline. Without a buyer or the ability to monetize the pipeline, it is completely worthless. Without profits or dilution, LPCN will run out of cash next year or early 2027, making a buyer/partner the only viable path toward achieving profitability and getting a higher market cap. What we want or what we choose to believe will not impact these facts, EVER. Trade carefully.
